Cell Processing at CAGT. Overview. Adrian P. Gee Center for Cell & Gene Therapy. CAGT Introduction

Size: px
Start display at page:

Download "Cell Processing at CAGT. Overview. Adrian P. Gee Center for Cell & Gene Therapy. CAGT Introduction"

Transcription

1 Cell Processing at CAGT Adrian P. Center for Cell & Gene Therapy CAGT Introduction Overview Facility Description Products prepared Flow cytometry Quality Control Quality Assurance 1

2 Center for Cell & Gene Therapy CAGT Component Parts Basic & Translational Research Clinical Treatment & Research 2

3 Feigin Center at TCH 15 th Floor Protocol & Regulatory Affairs 16 th Floor Offices and GMP facilities Primary Location 17 th Floor Translational Research Translational Research 17 th Floor Performs Pre GMP research and translation Performs Pre GMP research and translation ~ 80 staff, graduate students, post docs and PIs Excellent source of new GMP projects 3

4 GMP Facilities GMP History There has been a GMP facility at BCM since 1992 vector manufacturing Expanded on arrival of CAGT in 1998 Construction of GMP Cell Processing Subsequent reconstruction o of Vector Facility Moved to 16 th floor in

5 Construction 16 th Floor Feigin Center 5

6 Cell Processing Main Vector Production Facility 6

7 Special Processing Receiving & Storage 7

8 Cell Banks Quality Assurance & Control 8

9 Offices & Administration HVAC Systems Cell Processing Facility 60 air changes per hour Recirculated air 9

10 CPF Flowpath Cell Processing Facility Single corridor design HVAC Systems Vector Production Facility 60 air changes per hour 100% exhausted air 10

11 VPF Flowpath Vector Production Facility Clean & dirty corridors Quality Control Cell Processing Released Supplies Quality Assurance Quality Control Cell Storage Gowning Freezer Storage Flow Flow Cytometry Gowning Vector Production Materials Management Traffic Pattern Cell Processing Supplies Administration Pass through Offices & Administration QA Materials Management Supplies Gowning Swing Suites Vector Production QA 11

12 Range of Cell & Gene Therapy Products HPC Dendritic Cells Cytotoxic T Cells Natural Killer Cells Mesenchymal Stromal Cells Lymphoblastoid Cells Monocytes Viral Vectors Leukemia Cell Vaccines Products Manufactured Products Manufactured Hematopoietic Progenitor Cells (HPC) HPC, Marrow, Unmanipulated HPC, Marrow, Red cell-depleted HPC, Marrow, Plasma depleted HPC, Marrow, CD34 selected HPC, Apheresis, Plasma-depleted Marrow mononuclear cells (MNC) cardiac repair Marrow CD34-selected cardiac repair Marrow MNC traumatic brain injury Marrow MNC stroke patients HPC - Cord blood AC133-selected, ex vivo expanded For hearing loss & brain injury Lymphoblastoid cell lines +/- genetic modification Intermediate product Donor leukocytes (DLI) Hepatic progenitor cells Pancreatic islet cells allogeneic GMP-grade EBV NK Cells Products Manufactured Cytotoxic T cells (CTLS) CTLs EBV directed CTLs LMP2 directed CTLs LMP1/LMP2-directed CTLs Adenovirus directed CTLs tri-virus directed CTL EBV/Neuroblastoma directed CTL- Genetically modified (TGFβ etc) Genetically-modified allodepleted donor T lymphocytes Tumor vaccines +/- genetic modification TV autologous neuroblastoma-directed TV- allogeneic neuroblastoma-directed TV- autologous CLL-directed Mesenchymal stem/progenitor cells (MSC) Antigen presenting cells (APC) APC dendritic cells Intermediate product APC monocytes intermediate product APC gene modified leukemic cell lines 12

13 Flow Cytometry 4.5 Staff CAP accredited d 2BD Canto II & 1 Canto 6Lyse Wash Assistants Product analysis Mobilization Immune reconstitution Quality Control 7Staff Perform or send out all product testing Endosafe Mycoplasma Bioburden Viral titers EBV (for TCH) Recombinant virus detection Environmental monitoring 13

14 Quality Assurance 3 staff (1 TBA) Review production records Review equipment & environmental records Control documentation Training Proficiency i Competency Master Files Etc.etc. Audits GMP External Customers 14

15 Come & see the real thing! Tours available both afternoons 15

Challenges associated with supply to larger patients populations: Elements of the CTL019 experience

Challenges associated with supply to larger patients populations: Elements of the CTL019 experience Cell and Gene Therapy Challenges associated with supply to larger patients populations: Elements of the CTL019 experience Daniel Stark Head External Supply Cell- and Gene Therapies Development and Manufacturing

More information

Hematopoietic Stem Cells: Cell Processing, and Transplantation

Hematopoietic Stem Cells: Cell Processing, and Transplantation Hematopoietic Stem Cells: Cell Processing, and Transplantation Rona Singer Weinberg, PhD Director, Cellular Therapy Laboratory New York Blood Center Phone: (212) 570-3488 E-mail: rweinberg@nybloodcenter.org

More information

INTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION

INTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION INTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION Seventh Edition DRAFT May 2017 NOTICE These Standards are designed to provide minimum guidelines

More information

STANDARDS FOR IMMUNE EFFECTOR CELLS

STANDARDS FOR IMMUNE EFFECTOR CELLS STANDARDS FOR IMMUNE EFFECTOR CELLS January 2017 NOTICE These Standards are designed to provide minimum guidelines for programs, facilities, and individuals performing cellular therapy or providing support

More information

INTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION

INTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION INTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION Sixth Edition Version 6.1 NOTICE These Standards are designed to provide minimum guidelines

More information

PACT. PACT Program. Production Assistance for Cellular Therapies

PACT. PACT Program. Production Assistance for Cellular Therapies PACT Production Assistance for Cellular Therapies University of Wisconsin PACT-sponsored Workshop Developing Cellular Therapies: From Preclinical Safety To Clinical Evaluation Tuesday, April 09, 2013 Robert

More information

INTERNATIONAL STANDARDS FOR CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION FOR HEMATOPOIETIC CELLULAR THERAPIES

INTERNATIONAL STANDARDS FOR CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION FOR HEMATOPOIETIC CELLULAR THERAPIES INTERNATIONAL STANDARDS FOR CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION FOR HEMATOPOIETIC CELLULAR THERAPIES Draft Sixth Edition April 2014 NOTICE These Standards are designed to

More information

Case Study: Examples Relating to the Quality Control of Cell-based Products

Case Study: Examples Relating to the Quality Control of Cell-based Products Case Study: Examples Relating to the Quality Control of Cell-based Products CMC Strategy Forum Japan 2014 Yuuki Miyatake1), 2) 1) TEIJIN PHARMA LIMITED 2) Japan Pharmaceutical Manufacturers Association

More information

Clinical and Operational Infrastructure for Engineered Cell Therapy Delivery

Clinical and Operational Infrastructure for Engineered Cell Therapy Delivery Clinical and Operational Infrastructure for Engineered Cell Therapy Delivery Sarah Nikiforow, MD, PhD Dana-Farber Cancer Institute Clinical Instructor, Stem Cell Transplantation Assistant Medical Director

More information

Antibody-based HLA (Human Leucocyte Antigen ) tissue-typing technologies

Antibody-based HLA (Human Leucocyte Antigen ) tissue-typing technologies Human AB Serum Product Description Human AB Serum is a vital cell culture reagent for some human cell types providing growth factors, vitamins, nutrients as well as trace elements and transport factors,

More information

Regulatory Pathways for Rare Diseases

Regulatory Pathways for Rare Diseases Regulatory Pathways for Rare Diseases Celia M. Witten, Ph.D., M.D. Deputy Director, FDA Center for Biologics Evaluation and Research Emerging Technologies for Rare Diseases: Clinical and Regulatory Case

More information

Production Assistance for Cellular Therapies PACT

Production Assistance for Cellular Therapies PACT Production Assistance for Cellular Therapies PACT Traci Heath Mondoro, PhD NHLBI Bethesda, Maryland Renewed PACT Program Renewed January 15, 2010 Scope and size expanded Cell Processing Facilities (CPFs)

More information

FDA Oversight of Gene Therapy

FDA Oversight of Gene Therapy FDA Oversight of Gene Therapy Celia M. Witten, Ph.D., M.D. Deputy Director, FDA CBER Rare Disease and Orphan Products Breakthrough Summit NORD October 17, 2016 Hyatt Regency Crystal City Crystal City,

More information

PROTOCOL FOR A RESEARCH SAMPLE REPOSITORY FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, OTHER CELLULAR THERAPIES AND MARROW TOXIC INJURIES

PROTOCOL FOR A RESEARCH SAMPLE REPOSITORY FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, OTHER CELLULAR THERAPIES AND MARROW TOXIC INJURIES Center for International Blood and Marrow Transplant Research PROTOCOL FOR A RESEARCH SAMPLE REPOSITORY FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, OTHER CELLULAR THERAPIES AND MARROW TOXIC

More information

Advanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4. Relevant Financial Relationships - None

Advanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4. Relevant Financial Relationships - None EAHP March 2016 Advanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4 Dr. Lenka Taylor Pharmacy University Hospital Heidelberg Disclosure Relevant Financial Relationships

More information

Des cellules-souches dans le poumon : pourquoi faire?

Des cellules-souches dans le poumon : pourquoi faire? Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland

More information

Alphabetical Glossary of Terms. Gene Therapy & Immunotherapy for Cancer

Alphabetical Glossary of Terms. Gene Therapy & Immunotherapy for Cancer Alphabetical Glossary of Terms Gene Therapy & Immunotherapy for Cancer Introduction The purpose of this glossary is to provide clarification of the most commonly used terms related to cancer research and

More information

4000: Cellular Therapy Essential Data Pre- Infusion

4000: Cellular Therapy Essential Data Pre- Infusion 4000: Cellular Therapy Essential Data Pre- Infusion! This form must be completed for all recipients of cellular therapy (non-hct) where it is the first indication for treatment (no prior hematopoietic

More information

The promise of T cell engineering CD19 CAR therapy A prologue to immune regenerative medicine Vast potential, patience, public education

The promise of T cell engineering CD19 CAR therapy A prologue to immune regenerative medicine Vast potential, patience, public education The promise of T cell engineering CD19 CAR therapy A prologue to immune regenerative medicine Vast potential, patience, public education Academies Cell Therapy Workshop Washington, October 13, 2016 Michel

More information

At the conclusion of this lesson you should be able to:

At the conclusion of this lesson you should be able to: Learning Objectives At the conclusion of this lesson you should be able to: Understand the key terms and definitions regarding stem cells Differentiate between the adult and embryonic stem cells Differentiate

More information

CAP Accreditation Checklists 2017 Edition

CAP Accreditation Checklists 2017 Edition CAP Accreditation Checklists 2017 Edition The College of American Pathologists (CAP) accreditation checklists contain the CAP accreditation program requirements, developed on more than 50 years of insight

More information

What Are Stem Cells? Where Are These Stem Cells?

What Are Stem Cells? Where Are These Stem Cells? While stem cell therapies may seem to have appeared overnight, they have been practiced for some time prior to the recent burst in new applications and stem cell sources. The most recent developments in

More information

Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective

Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective CASSS CMC Summer Forum 2017 Chris Storbeck, PhD Health Canada Outline Health Canada organization Regulation of

More information

Clinical Applications of Mesenchymal Stromal Cells

Clinical Applications of Mesenchymal Stromal Cells Clinical Applications of Mesenchymal Stromal Cells John Girdlestone PhD Stem Cells and Immunotherapies NHS Blood and Transplant, Oxford John Radcliffe Hospital Mesenchymal Stromal Cells (MSC) Fibroblastic,

More information

Cell Therapy Services Your Product. Our Passion.

Cell Therapy Services Your Product. Our Passion. Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing

More information

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects

More information

CHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS

CHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS CHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS Maria Cristina Galli, Ph.D. Istituto Superiore di Sanità Roma, Italy EATRIS ATMP platform chair ISCT 2016 Global Regulatory Perspective Workshop

More information

Exhibit Floorplan update Grand Ballroom ABCD

Exhibit Floorplan update Grand Ballroom ABCD Exhibit Floorplan update Grand Ballroom ABCD 100 102 104 106 Booth # Company/Organization 100 Lonza Walkersville, Inc. 101 Compass Biomedical 102 stemtrak 101 105 109 104 Biosafe America, Inc. 105 Waisman

More information

Stem Cell Services. Driving Innovation for Stem Cell Researchers

Stem Cell Services. Driving Innovation for Stem Cell Researchers Driving Innovation for Stem Cell Researchers Stem Cell Services Partner with us and have access to the most advanced and comprehensive stem cell services available today. 675 W. Kendall St. Cambridge,

More information

Long-Term Follow-Up in Gene Transfer Clinical Research

Long-Term Follow-Up in Gene Transfer Clinical Research Long-Term Follow-Up in Gene Transfer Clinical Research Jan P. Vleck, MD CIP Institutional Biosafety Committee Services A Division of WIRB www.ibcservicepoint.com ibcs@wirb.com What is LTFU? the collection

More information

ISBT 128 coding system and the Single European Code: Introduction. Presented by: Jessy Lardon

ISBT 128 coding system and the Single European Code: Introduction. Presented by: Jessy Lardon ISBT 128 coding system and the Single European Code: Introduction Presented by: Jessy Lardon Single European Code (= SEC) The SEC is the unique identifier applied to tissues and cells distributed in the

More information

HSC enumeration of fresh samples

HSC enumeration of fresh samples HSC enumeration of fresh samples Claude LEMARIÉ QC Facility Medical Director Cell Therapy Facility, Centre de Thérapie Cellulaire, Département de Biologie du Cancer, Institut Paoli-Calmettes, Comprehensive

More information

Update from the Center for Biologics Evaluation and Research (CBER): Advancing the Development of Complex Biologic Products

Update from the Center for Biologics Evaluation and Research (CBER): Advancing the Development of Complex Biologic Products Update from the Center for Biologics Evaluation and Research (CBER): Advancing the Development of Complex Biologic Products Peter Marks, M.D., Ph.D. FDLI 2017 Outline Products regulated Significance of

More information

Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach

Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach 3 July 2017 EMA/CAT/216556/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the

More information

Process Robustness & Challenges to Demonstrating Compliance

Process Robustness & Challenges to Demonstrating Compliance Process Robustness & Challenges to Demonstrating Compliance Nick Smith Head of Production & TSS 2 nd March 2017 95% Thomas Eldered 5% Management Headcount : 270 3 GMP facilities Cobra s Structure Cobra

More information

Measurement of Hematopoietic Stem Cell Potency Prior to Transplantation

Measurement of Hematopoietic Stem Cell Potency Prior to Transplantation WHITE PAPER Measurement of Hematopoietic Stem Cell Potency Prior to Transplantation February, 2009 This White Paper is a forward-looking statement. It represents the present state of the art and future

More information

Hematopoietic Stem Cells

Hematopoietic Stem Cells Hematopoietic Stem Cells ISOLATE & CULTURE VERIFY DIFFERENTIATE INVESTIGATE ISOLATE AND CULTURE Mouse Hematopoietic Cell Lineage Depletion Kit ( MAGM29) Both positive and negative selection methods can

More information

Immunogenicity of Stem Cells in Therapeutic Applications. MDPB-Registry meeting nov 25th Stem cell immunogenicity in therapeutic applications

Immunogenicity of Stem Cells in Therapeutic Applications. MDPB-Registry meeting nov 25th Stem cell immunogenicity in therapeutic applications Immunogenicity of Stem Cells in Therapeutic Applications MDPB-Registry meeting nov 25th 2016 Stem cell immunogenicity in therapeutic applications Has it been underestimated? Transplantation of any type

More information

HSV-2 therapeutic vaccine program. Subunit vaccine candidates

HSV-2 therapeutic vaccine program. Subunit vaccine candidates HSV-2 therapeutic vaccine program Subunit vaccine candidates Our HSV-2 vaccine program Therapeutic subunit vaccine T-cell-based Aim: Best-in-class antigens by engineering Excellent standing (Sept 2017):

More information

Hematopoietic stem. Hematopoietic Stem and Progenitor Cells. Congenital immune deficiencies severe combined immunodeficiency

Hematopoietic stem. Hematopoietic Stem and Progenitor Cells. Congenital immune deficiencies severe combined immunodeficiency 23 Hematopoietic Stem and Progenitor Cells Hematopoietic stem cells are those cells capable of self-renewal and of differentiation into any blood-cell lineage. By contrast, progenitor cells are committed

More information

Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT)

Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT) Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT) Görgün Akpek, MD, MHS Director, SCT and Cellular Therapy Program Banner MD Anderson Cancer Center GAkpek@mdanderson.org MULTIPLE MYELOMA

More information

Hematopoietic Stem Cells

Hematopoietic Stem Cells Hematopoietic Stem Cells Isolate Culture Verify Differentiate Investigate a brand Hematopoietic Stem Cells Hematopoietic stem cells (HSCs) are multipotent, self-renewing progenitor cells from which all

More information

Issues in production of viral gene transfer vectors. Stefan Kochanek Department of Gene Therapy Ulm University

Issues in production of viral gene transfer vectors. Stefan Kochanek Department of Gene Therapy Ulm University Issues in production of viral gene transfer vectors Stefan Kochanek Department of Gene Therapy Ulm University Only few positive results in gene therapy so far - many early phase, few late phase clinical

More information

Where are we with gene therapy?

Where are we with gene therapy? Where are we with gene therapy? Session 9: Gene Based Therapies Professor Alan Boyd PFPM 7 th February 2018 Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians, UK Topics to be covered Gene

More information

Regulatory Requirements for CRISPR Therapeutics. Bill Lundberg, MD February 2017

Regulatory Requirements for CRISPR Therapeutics. Bill Lundberg, MD February 2017 Regulatory Requirements for CRISPR Therapeutics Bill Lundberg, MD February 2017 Forward Looking Statements This document contains forward-looking statements within the meaning of the safe harbor provisions

More information

Catalog # Product Size PRIME-XV Hematopoietic Cell Basal XSFM 500 ml (liquid) Additional package sizes are available at request

Catalog # Product Size PRIME-XV Hematopoietic Cell Basal XSFM 500 ml (liquid) Additional package sizes are available at request PRIME-XV HEMATOPOIETIC CELL BASAL XSFM PRIME-XV Hematopoietic Cell Basal XSFM is an optimized xeno- and serum free media recommended for use in the expansion of human hematopoietic cells, including hematopoietic

More information

HCT/P Regulation vs 361 Products

HCT/P Regulation vs 361 Products HCT/P Regulation - 351 vs 361 Products Presented by: Paul Gadiock February 15, 2017 Arent Fox LLP Washington, DC New York, NY Los Angeles, CA San Francisco, CA 1 Presentation Overview Introduction Public

More information

Quality Control in Flow. Dr David Westerman Head of Haematopathology Peter MacCallum Cancer Centre

Quality Control in Flow. Dr David Westerman Head of Haematopathology Peter MacCallum Cancer Centre Quality Control in Flow Dr David Westerman Head of Haematopathology Peter MacCallum Cancer Centre Aims Quality Assurance Quality Control Literature In house competencies SHOT DATA 1996-2009 Ref: SHOT Annual

More information

Research Xchange Forum 2018

Research Xchange Forum 2018 Research Xchange Forum 2018 Insights Translation Solutions Trends and Challenges in Regenerative Medicine & Cell Therapy March 20 21, 2018 Sartorius Goettingen, Germany What to expect Learn about the latest

More information

Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services

Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations Audrey Chang, PhD, Senior Director Development Services Definition of Biologics: PHS Act, section 351 Virus, therapeutic

More information

COMMISSION OF THE EUROPEAN COMMUNITIES. Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

COMMISSION OF THE EUROPEAN COMMUNITIES. Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 19.6.2002 COM(2002) 319 final 2002/0128(COD) Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on setting standards of quality and

More information

Several cellular therapies are

Several cellular therapies are B i op r o c e s s Technical Manufacturing Patient-Specific Cell Therapy Products An Overview and Case Study of Tissue Repair Cell Technology Brian Hampson, Jon Rowley, and Naia Venturi Several cellular

More information

Medical Issues in a Clinical Cellular Therapy Laboratory. Kala Mohandas, MD Director, Cellular Therapy Lab Montefiore Medical Center Bronx, NY

Medical Issues in a Clinical Cellular Therapy Laboratory. Kala Mohandas, MD Director, Cellular Therapy Lab Montefiore Medical Center Bronx, NY Medical Issues in a Clinical Cellular Therapy Laboratory Kala Mohandas, MD Director, Cellular Therapy Lab Montefiore Medical Center Bronx, NY Objectives Major, Minor and Bidirectional ABO Incompatibility

More information

The challenges of potency assay development for cell-based medicinal products in Europe

The challenges of potency assay development for cell-based medicinal products in Europe Focus Advanced therapies 5 The challenges of potency assay development for cell-based medicinal products in Europe Authors Valerie Pimpaneau, Senior Director, Voisin Consulting Life Sciences; François

More information

Prioritization of Neoantigens without Predictions: Comprehensive T cell Screening using ATLAS

Prioritization of Neoantigens without Predictions: Comprehensive T cell Screening using ATLAS Prioritization of Neoantigens without Predictions: Comprehensive T cell Screening using ATLAS Jessica Baker Flechtner, PhD CSO, Genocea Biosciences 15 November 2016 1 Safe Harbor Statement This presentation

More information

Guide to Clonetics and Poietics Cell Types

Guide to Clonetics and Poietics Cell Types Guide to Clonetics and Poietics Cell Types Clonetics and Poietics Cell Types - Sorted By Tissue Source Cryopreserved Human Cells Adipose Subcutaneous Preadipocytes PT-5001 PGM -2 PT-8002 Visceral Preadipocytes

More information

Immunotherapy in Hemato-Oncology

Immunotherapy in Hemato-Oncology ESMO Preceptorship Programme Immuno-Oncology From tumor immunology to clinical application 2-3 November 2016 Zurich - CH Immunotherapy in Hemato-Oncology Markus G. Manz Klinikdirektor Hämatologie USZ Leiter

More information

Bill Kabat and Carmen Irizarry of the ACTG/IMPAACT Lab Tech Committee. Network Name, Title Signature Date

Bill Kabat and Carmen Irizarry of the ACTG/IMPAACT Lab Tech Committee. Network Name, Title Signature Date Title: Dried PBMC Pellet Processing Standard Operating Procedure (LDMS specimen code = BLD/EDTA or ACD/PEL) Origination Date: 01 Jun 2004 Total Pages: 6 Effective Date: 29 Nov 2012 SOP Number LTC-SOP-59

More information

Janice Soreth, M.D. Deputy Director FDA Europe Office Liaison to EMA. Making Gene and Cell Therapy a Reality July 10-11, 2012 Dublin

Janice Soreth, M.D. Deputy Director FDA Europe Office Liaison to EMA. Making Gene and Cell Therapy a Reality July 10-11, 2012 Dublin Janice Soreth, M.D. Deputy Director FDA Europe Office Liaison to EMA Making Gene and Cell Therapy a Reality July 10-11, 2012 Dublin Acknowledgments Celia Witten, Ph.D., M.D. Director Office of Cellular,

More information

Cellometer Vision CBA

Cellometer Vision CBA Features of the Vision CBA Image Cytometry System All-in-One System Basic cell counting, primary cell viability, and cellbased assays. See for Yourself Why the Top Ten Pharmaceutical Companies Trust Cellometer

More information

GREAT STRIDES IN SCIENCE WHAT ABOUT ACCESS? Marlene E. Haffner, MD, MPH 2nd IRDiRC Conference Shenzhen, China November 8, 2014

GREAT STRIDES IN SCIENCE WHAT ABOUT ACCESS? Marlene E. Haffner, MD, MPH 2nd IRDiRC Conference Shenzhen, China November 8, 2014 GREAT STRIDES IN SCIENCE WHAT ABOUT ACCESS? Marlene E. Haffner, MD, MPH 2nd IRDiRC Conference Shenzhen, China November 8, 2014 1982 WHAT HAS HAPPENED SINCE IN TECHNOLOGY ASSESSMENT AND. US Orphan Drug

More information

INDUSTRY PERSPECTIVE: REGULATORY ASPECTS OF DEVELOPING PERSONALIZED CANCER VACCINES

INDUSTRY PERSPECTIVE: REGULATORY ASPECTS OF DEVELOPING PERSONALIZED CANCER VACCINES INDUSTRY PERSPECTIVE: REGULATORY ASPECTS OF DEVELOPING PERSONALIZED CANCER VACCINES Kathleen Francissen, Ph.D. Senior Director, CMC Regulatory Genentech, A Member of the Roche Group ISPE Biopharmaceutical

More information

2. The Principles of Dynabeads

2. The Principles of Dynabeads 2. The Principles of What Are? 9 How Are Used? 9 Different Types of 10 Surface Activated, Primary and Secondary-Coated 10 Small and Large 10 Different Separation Strategies 11 Positive Isolation: Binding

More information

Efficacy of CD 25 blockade as targeted adjuvant therapy in the prevention of GVHD in pediatric stem cell transplant recipients

Efficacy of CD 25 blockade as targeted adjuvant therapy in the prevention of GVHD in pediatric stem cell transplant recipients Aus der Universitätsklinik und Poliklinik für Kinder- und Jugendmedizin an der Martin-Luther-Universität Halle-Wittenberg Direktor: Prof. Dr. med. St. Burdach Efficacy of CD 25 blockade as targeted adjuvant

More information

Biotechnology Projects. What do NTHRYS Provide under these Project Works?

Biotechnology Projects. What do NTHRYS Provide under these Project Works? Biotechnology Projects NTHRYS provides Biotechnology Projects for interested candidates at its Hyderabad facility, Telangana. Please refer below for more details including Fee strctures, Eligibility, Protocols

More information

AUTOIMMUNE HEPATITIS EXPERIMENTAL MODEL BASED ON. Sainte-Justine University Hospital, Montreal (Quebec), H3T 1C5, Canada; 3 Departments

AUTOIMMUNE HEPATITIS EXPERIMENTAL MODEL BASED ON. Sainte-Justine University Hospital, Montreal (Quebec), H3T 1C5, Canada; 3 Departments 1 2 AUTOIMMUNE HEPATITIS EXPERIMENTAL MODEL BASED ON ADENOVIRAL INFECTIONS 3 4 Authors: Pascal Lapierre 1, Kathie Béland 2 and Fernando Alvarez 2,3,4 5 6 7 Affiliations: 1 Immunovirology Laboratory, INRS-Institut

More information

Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development

Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development For reprint orders, please contact: reprints@futuremedicine.com Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development A major challenge

More information

Application of Quality Risk Management Tools for Cell Therapy Manufacturing

Application of Quality Risk Management Tools for Cell Therapy Manufacturing Application of Quality Risk Management Tools for Cell Therapy Manufacturing 17 th ISCT Annual Meeting May 20, 2011 Jean Stanton Associate Director, Product Quality Management Janssen Supply Chain Conflict/Disclaimer

More information

Direct Cell Counting Assays for Immuno Therapy

Direct Cell Counting Assays for Immuno Therapy Direct Cell Counting Assays for Immuno Therapy Cytotoxicity assays play a central role in studying the function of immune effector cells such as cytolytic T lymphocytes (CTL) and natural killer (NK) cells.

More information

Blood Product Utilization

Blood Product Utilization Who gets what & when Why not to give blood? Volume Expander For specific number (except as related to procedures) To patients with religious objections to blood transfusions Blood given only when necessary

More information

Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD

Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD Platelet Refractoriness: The Basics Martin H. Bluth, MD, PhD Complete Toxicology Laboratories, LLC Objectives Define platelet refractoriness and associated conditions that may cause platelet refractoriness.

More information

Immuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma

Immuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma Immuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma Stanley R. Frankel, MD, FACP Corporate Vice President, Clinical R & D Head, Immuno-Oncology Celgene Cancer Progress

More information

FDA Perspectives On Viral & Vector Shedding Studies. Daniel Takefman, Ph.D. Chief, Gene Therapy Branch FDA/CBER ICH Workshop: October 31, 2007

FDA Perspectives On Viral & Vector Shedding Studies. Daniel Takefman, Ph.D. Chief, Gene Therapy Branch FDA/CBER ICH Workshop: October 31, 2007 FDA Perspectives On Viral & Vector Shedding Studies Daniel Takefman, Ph.D. Chief, Gene Therapy Branch FDA/CBER ICH Workshop: October 31, 2007 Overview Define shedding studies Outline basis for need of

More information

GMO Technology Conference

GMO Technology Conference GMO Technology Conference The regulation of Clinical Trials on humans involving therapies containing or consisting of genetically modified organisms The Printworks, Dublin Castle 10 th & 11 th October

More information

Supplemental Information Inventory

Supplemental Information Inventory Cell Stem Cell, Volume 6 Supplemental Information Distinct Hematopoietic Stem Cell Subtypes Are Differentially Regulated by TGF-β1 Grant A. Challen, Nathan C. Boles, Stuart M. Chambers, and Margaret A.

More information

Blue Marble University Biology Course Handbook

Blue Marble University Biology Course Handbook Blue Marble University Biology Course Handbook A Summary of Course Descriptions Courses and Content Subject to Change Without Notice BlueMarbleUniversity.com Info@bluemarbleuniversity.com Stem Cell Biology

More information

Bringing the EuroFlow Concept

Bringing the EuroFlow Concept Bringing the EuroFlow Concept Cytognos - EuroFlow Supporting Company Company Overview Cytognos provides through worldwide distribution a broad range of reagents and software for flow cytometry applications

More information

EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER

EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER Disclaimer: This example is just one potential example of a vendor qualification form to verify the adequacy of the internal

More information

Paresh Vishwasrao. M.Sc. Zoology, Molecular Biology, University of Pune, MH, India

Paresh Vishwasrao. M.Sc. Zoology, Molecular Biology, University of Pune, MH, India Paresh Vishwasrao 1 Phone #: (201) 491 3741 Email: vishwasrao.paresh@gmail.com Webpage: http://developinginsights.org Education: Ph.D. Translation Immunology and Immunotherapy, 2011-2017 Academic Med Center

More information

Gene therapy in rare anemias

Gene therapy in rare anemias Gene therapy in rare anemias Jose Carlos Segovia Differentiation and Cytometry Unit. Hematopoietic Innovative Therapies Division CIEMAT-CIBER / IIS-FJD Madrid - Spain 6 th EUROPEAN SYMPOSIUM ON RARE ANAEMIAS

More information

Regulatory Implications for Global Manufacturing Development of Regenerative Medicines

Regulatory Implications for Global Manufacturing Development of Regenerative Medicines Regulatory Implications for Global Manufacturing Development of Regenerative Medicines Katherine Tsokas, JD June 2017 Global Regulatory Affairs Janssen Research & Development, LLC Jessica Riley, Shells

More information

Immunotherapy in myeloma

Immunotherapy in myeloma Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to

More information

PERFECT-COUNT MICROSPHERES

PERFECT-COUNT MICROSPHERES PERFECT-COUNT MICROSPHERES Perfect-Count Microspheres-Product code PCB-100 for 100 tests Introduction In recent years, the determination of absolute cell counts has been shown to be relevant in different

More information

Adult Stem Cells by David A. Prentice, Ph.D.

Adult Stem Cells by David A. Prentice, Ph.D. Adult Stem Cells by David A. Prentice, Ph.D. Within just a few years, the possibility that the human body contains cells that can repair and regenerate damaged and diseased tissue has gone from an unlikely

More information

Cells (DPSCs) that show high selfrenewal and peripheral blood have been compatible donor, who was a

Cells (DPSCs) that show high selfrenewal and peripheral blood have been compatible donor, who was a NEWS 03 March 2008 www.biohellenika.gr Biohellenika SA is the only Accredited by ÅÓÕÄ Stem Cell Cryopreservation Company Clinical applications of umbilical cord blood stem cells for nonmalignant diseases

More information

Quality Management. Carlos Bachier, MD

Quality Management. Carlos Bachier, MD Quality Management Carlos Bachier, MD Goals of Quality Management Ensure credibility of outcomes Improve patient safety and quality of processes Significantly reduce errors Quality Medical and Laboratory

More information

US FDA: CMC Issues for INDs

US FDA: CMC Issues for INDs ISBTC Global Regulatory Summit October 29, 2008 US FDA: CMC Issues for INDs Keith Wonnacott, Ph.D. keith.wonnacott@fda.hhs.gov US Food and Drug Administration Center for Biologics Evaluation and Research

More information

Adipose rabbit mesenchymal stem cells for the treatment of the chronic scar tissue of the vocal cords

Adipose rabbit mesenchymal stem cells for the treatment of the chronic scar tissue of the vocal cords Adipose rabbit mesenchymal stem cells for the treatment of the chronic scar tissue of the vocal cords Dr. Vasiliki E Kalodimou, Head of Flow Cytometry-Research and Regenerative Medicine Department, IASO-Maternity

More information

TEPZZ 79 6 B_T EP B1 (19) (11) EP B1 (12) EUROPEAN PATENT SPECIFICATION

TEPZZ 79 6 B_T EP B1 (19) (11) EP B1 (12) EUROPEAN PATENT SPECIFICATION (19) TEPZZ 79 6 B_T (11) EP 2 791 163 B1 (12) EUROPEAN PATENT SPECIFICATION () Date of publication and mention of the grant of the patent: 01.03.17 Bulletin 17/09 (21) Application number: 12870.0 (22)

More information

Technical Applications Track 2 Safety Testing for Cell Therapy Products: Requirements, Relevance, and New Technologies

Technical Applications Track 2 Safety Testing for Cell Therapy Products: Requirements, Relevance, and New Technologies ISCT Annual Meeting Rotterdam, The Netherlands 19 May 2011 Technical Applications Track 2 Safety Testing for Cell Therapy Products: Requirements, Relevance, and New Technologies Speakers Scott Burger (USA)

More information

No-wash, no-lyse detection of phagocytic cells via a phrodo BioParticles functional assay in human whole blood on the

No-wash, no-lyse detection of phagocytic cells via a phrodo BioParticles functional assay in human whole blood on the APPLICATION NOTE Attune NxT Flow Cytometer No-wash, no-lyse detection of phagocytic cells via a phrodo BioParticles functional assay in human whole blood on the Attune NxT Flow Cytometer Introduction Analysis

More information